This document is a published patent application from the USPTO, specifically application US20260083785A1, filed on September 27, 2023. It describes the use of a Bifidobacterium longum transitional microorganism for preventing or reducing the risk of infection in infants and young children.

As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on entities. However, it signals potential future developments in therapeutic applications for probiotics in pediatric health. Companies involved in the development or manufacturing of probiotics, infant formula, or pediatric therapeutics should monitor the progress of this and similar patent applications as they may impact intellectual property landscapes and future product innovation in the sector.